William Strohl Net Worth

William Strohl biography

Dr. William Strohl Ph.D. serves as Independent Director of the Company. Dr. Strohl founded BiStro Biotech Consulting, a biotechnology consulting company, of which he also serves as President. From February 2016 to August 2016, Dr. Strohl served as Vice President and Biologics Fellow at Janssen BioTherapeutics, the therapeutic biologics organization within the Janssen Research & Development division of Johnson & Johnson, a multinational medical devices and pharmaceutical company, and served as its Vice President and Head from October 2013 to February 2016. Prior to that, from April 2008 to October 2013, Dr. Strohl served as Head of Antibody Discovery at Janssen BioTherapeutics. Dr. Strohl has also held various roles at Merck, a pharmaceutical company, including leading Natural Products Biology and leading Biologics discovery efforts and was a Professor in the Department of Microbiology and the Program of Biochemistry at The Ohio State University. Dr. Strohl received a B.S. in Biology from Central Michigan University and a Ph.D. in Microbiology from Louisiana State University.

What is the salary of William Strohl?

As the Independent Director of IGM Biosciences, the total compensation of William Strohl at IGM Biosciences is $163,766. There are 11 executives at IGM Biosciences getting paid more, with Fred M. Schwarzer J.D. having the highest compensation of $926,901.

How old is William Strohl?

William Strohl is 67, he's been the Independent Director of IGM Biosciences since 2019. There are 4 older and 13 younger executives at IGM Biosciences. The oldest executive at IGM Biosciences, Inc. is Michael Loberg, 72, who is the Independent Chairman of the Board.

What's William Strohl's mailing address?

William's mailing address filed with the SEC is C/O IGM BIOSCIENCES, INC., 325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW, CA, 94043.

Insiders trading at IGM Biosciences

Over the last 5 years, insiders at IGM Biosciences have traded over $2,263,330 worth of IGM Biosciences stock and bought 10,358,723 units worth $195,788,133 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Group, Llc Green Jeremy Red... a Bros. Advisors Lp667, L.P.B.... On average, IGM Biosciences executives and independent directors trade stock every 13 days with the average trade being worth of $942,182. The most recent stock trade was executed by Julie Hambleton on 25 July 2024, trading 15,132 units of IGMS stock currently worth $21,033.

What does IGM Biosciences do?

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

IGM Biosciences executives and stock owners

IGM Biosciences executives and other stock owners filed with the SEC include:

• Fred M. Schwarzer J.D.,
  CEO, Pres & Director
• Fred Schwarzer,
  President, Chief Executive Officer, Director
• Dr. Shinyu Chen M.D., Ph.D.,
  Consultant
• Dr. Chris H. Takimoto FACP, M.D., Ph.D.,
  Chief Medical Officer
• Dr. Bruce A. Keyt,
  Chief Scientific Officer
• Fred M. Schwarzer,
  CEO, Pres & Director
• Bruce Keyt,
  Chief Scientific Officer
• Misbah Tahir,
  Chief Financial Officer
• Michael Loberg,
  Independent Chairman of the Board
• M. Kathleen Behrens,
  Independent Director
• Julie Hambleton,
  Independent Director
• William Strohl,
  Independent Director
• Christina Topsoe,
  Independent Director
• Kelvin Neu,
  Independent Director
• Jakob Topsoe,
  Independent Director
• Michael Lee,
  Independent Director
• David Pitts,
  IR Contact Officer
• Daniel Chen,
  Chief Medical Officer
• Steven Weber,
  SVP, Corp. Controller & Principal Accounting Officer
• Marvin S. Peterson Ph.D.,
  Sr. VP, Process Sciences & Manufacturing
• George A. Gauthier,
  Chief Commercial Officer
• Dr. Lisa L. Decker Ph.D.,
  Chief Bus. Officer
• Misbah Tahir,
  Chief Financial Officer
• Angus Sinclair,
  VP of Immuno-Oncology
• Suzette Tauber,
  VP of HR
• Paul C. Graffagnino,
  VP of Legal Affairs
• Mary Beth Harler,
  Head, Research & Autoimmunity
• Group, Llc Green Jeremy Red...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Holding A/S Topsoe,
  10% owner
• Chris H Takimoto,
  CHIEF MEDICAL OFFICER
• Bros. Advisors Lp667, L.P.B...,
  
• Lisa Lynn Decker,
  CHIEF BUSINESS OFFICER
• George Gauthier,
  Chief Commercial Officer
• Steven Weber,
  PRINCIPAL ACCOUNTING OFFICER
• Elizabeth H.Z. Thompson,
  
• Bros. Advisors Lp667, L.P.B...,